Boston Scientific Corp. vs. Integra LifeSciences Holdings
Boston Scientific Corp. (BSX) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| BSX | IART | |
|---|---|---|
| Market Cap | $62.65 billion | $1.25 billion |
| Revenue (TTM) | $21.00 billion | $1.65 billion |
| Net Income (TTM) | $3.67 billion | $-7,242,000 |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | IART | |
|---|---|---|
| P/E Ratio | 17.34 | — |
| Price / Book | 2.49 | 1.20 |
| Price / Sales | 2.98 | 0.76 |
IART leads on 2 of 2 valuation factors.
Profitability
| BSX | IART | |
|---|---|---|
| Net Margin | 17.47% | -0.44% |
| Return on Equity | 14.58% | -0.69% |
BSX leads on 2 of 2 profitability factors.
Risk & Sentiment
| BSX | IART | |
|---|---|---|
| Short Interest | 0.72% | 6.92% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, IART overview, IART financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.